Journal of Pain and Symptom Management
Volume 38, Issue 5 , Pages 747-757 , November 2009

Morphine Inhalation by Cancer Patients: A Comparison of Different Nebulization Techniques Using Pharmacokinetic, Spirometric, and Gasometric Parameters

  • Małgorzata Krajnik, MD

      Affiliations

    • Department of Palliative Care, Collegium Medicum, Nicolas Copernicus University, Bydgoszcz, Poland
    • Corresponding Author InformationAddress correspondence to: Małgorzata Krajnik, MD, Department of Palliative Care, Collegium Medicum, Nicolas Copernicus University, Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.
    • ,
  • Zygmunt Podolec, MD

      Affiliations

    • Department of Aerosology and Aerosol Bioengineering, Research and Development Centre of MEDiNET, Krakow, Poland
    • ,
  • Monika Siekierka, MSci

      Affiliations

    • Department of Physiology, Collegium Medicum, Nicolas Copernicus University, Bydgoszcz, Poland
    • ,
  • Marzena Sykutera, MSci

      Affiliations

    • Department of Forensic Medicine, Collegium Medicum, Nicolas Copernicus University, Bydgoszcz, Poland
    • ,
  • Ewa Pufal, MD

      Affiliations

    • Department of Forensic Medicine, Collegium Medicum, Nicolas Copernicus University, Bydgoszcz, Poland
    • ,
  • Piotr Sobanski, MD

      Affiliations

    • Cardiology Department, II University Hospital, Bydgoszcz, Poland
    • ,
  • Roman Makarewicz, MD, PhD

      Affiliations

    • Department of Oncology, Collegium Medicum, Nicolas Copernicus University, Bydgoszcz, Poland
    • ,
  • Cees Neef, PharmD, PhD

      Affiliations

    • Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands
    • ,
  • Nieko Punt, MSci

      Affiliations

    • Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands
    • ,
  • Zbigniew Zylicz, MD, PhD

      Affiliations

    • Dove House Hospice, Hull, United Kingdom

,Accepted 1 April 2009.

References 

  1. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–944
  2. Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29:613–618
  3. Coyne PJ. The use of nebulized fentanyl for the management of dyspnea. Clin J Oncol Nurs. 2003;7:334–335
  4. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007;52:900–910
  5. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008;36:29–38
  6. Ray NJ, Jones AJ, Keen P. Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro. Br J Pharmacol. 1991;102:797–800
  7. Auberson S, Lacroix JS, Kordestani RK, Lundberg JM. Prejunctional control of pH 6-induced bronchoconstriction by NK1, NK2, mu-opioid, alpha2-adrenoceptor and glucocorticoid receptors in guinea-pig isolated perfused lung. J Pharm Pharmacol. 1998;50:899–905
  8. Lindstrom EG, Andersson RG. Morphine modulates contractile responses and neurokinin A-LI release elicited by electrical field stimulation or capsaicin in a guinea pig bronchial-tube preparation. Am J Respir Crit Care Med. 1995;151:1175–1179
  9. Belvisi MG, Stretton CD, Verleden GM, et al. Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol. 1992;72:1096–1100
  10. Fischer A, Undem BJ. Naloxone blocks endomorphin-1 but not endomorphin-2 induced inhibition of tachykinergic contractions of guinea-pig isolated bronchus. Br J Pharmacol. 1999;127:605–608
  11. Rogers DF, Barnes PJ. Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1989;1:930–932
  12. Lei YH, Rogers DF. Effects and interactions of opioids on plasma exudation induced by cigarette smoke in guinea pig bronchi. Am J Physiol. 1999;276:L391–L397
  13. Karlsson JA, Lanner AS, Persson CG. Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther. 1990;252:863–868
  14. Cabot PJ, Dodd PR, Cramond T, Smith MT. Characterization of non-conventional opioid binding sites in rat and human lung. Eur J Pharmacol. 1994;268:247–255
  15. Bhargava HN, Villar VM, Cortijo J, Morcillo EJ. Binding of [3H][D-Ala2, MePhe4, Gly-ol5] enkephalin, [3H][D-Pen2, D-Pen5]enkephalin, and [3H]U-69,593 to airway and pulmonary tissues of normal and sensitized rats. Peptides. 1997;18:1603–1608
  16. Cabot PJ, Cramond T, Smith MT. Quantitative autoradiography of peripheral opioid binding sites in rat lung. Eur J Pharmacol. 1996;310:47–53
  17. Sunday ME, Haley KJ, Emanuel RL, et al. Fetal alveolar epithelial cells contain [D-Ala(2)]-deltorphin I-like immunoreactivity: delta- and mu-opiate receptors mediate opposite effects in developing lung. Am J Respir Cell Mol Biol. 2001;25:447–456
  18. Krajnik M, Mousa SA, Stein C, et al. Opioid receptors and endogenous opioids in human lung tissue. Proceedings of the 11th World Congress on Pain, Sydney, Australia, 2005:419.
  19. Podolec P, Kaznica-Wiatr M, Podolec Z, et al. [Vasodilatator testing with nitric oxide (bronchial control treatment system—BCTS) in patients with pulmonary hypertension], [Polish] Przegl Lek. 2004;61:737–742
  20. Krajnik M, Podolec Z, Zylicz Z, Jassem E. Air humidity may influence the aerosol distribution of normal saline administered by closed or vented nebulizers operated continuously or dosimetrically. J Aerosol Med Pulm Drug Deliv. 2009;22–34
  21. Wilcock A, Crosby V, Clarke D, Corcoran R, Tattersfield A. Reading numbers aloud: a measure of the limiting effect of breathlessness in patients with cancer. Thorax. 1999;54:1099–1103
  22. Ward RJ, Ward C, Johns DP, et al. European Community Respiratory Health Survey calibration project of dosimeter driving pressures. Eur Respir J. 2002;19:252–256
  23. Bogusz MJ, Maier RD, Driessen S. Morphine, morphine-3-glucuronide, morphine-6-glucuronide, and 6-monoacetylmorphine determined by means of atmospheric pressure chemical ionization-mass spectrometry-liquid chromatography in body fluids of heroin victims. J Anal Toxicol. 1997;21:346–355
  24. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155–163
  25. Brack A, Rittner HL, Machelska H, et al. Endogenous peripheral antinociception in early inflammation is not limited by the number of opioid-containing leukocytes but by opioid receptor expression. Pain. 2004;108:67–75
  26. Mousa SA, Straub RH, Schafer M, Stein C. Beta-endorphin, met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis. 2007;66:871–879
  27. Mousa SA, Bopaiah CP, Richter JF, Yamdeu RS, Schafer M. Inhibition of inflammatory pain by CRF at peripheral, spinal and supraspinal sites: involvement of areas coexpressing CRF receptors and opioid peptides. Neuropsychopharmacology. 2007;32:2530–2542
  28. Risdahl JM, Huether MJ, Gustafson KV, Molitor TW. Morphine alteration of histamine release in vivo. Adv Exp Med Biol. 1995;373:161–168
  29. Schurig JE, Cavanagh RL, Buyniski JP. Effect of butorphanol and morphine on pulmonary mechanics, arterial blood pressure and venous plasma histamine in the anesthetized dog. Arch Int Pharmacodyn Ther. 1978;233:296–304
  30. Brashear RE, Kelly MT, White AC. Elevated plasma histamine after heroin and morphine. J Lab Clin Med. 1974;83:451–457
  31. Otulana B, Okikawa J, Linn L, Morishige R, Thipphawong J. Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. Int J Clin Pharmacol Ther. 2004;42:456–462
  32. Ward ME, Woodhouse A, Mather LE, et al. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther. 1997;62:596–609
  33. Dershwitz M, Walsh JL, Morishige RJ, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology. 2000;93:619–628
  34. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504
  35. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol. 2003;95:2106–2112
  36. Christrup LL, Sjogren P, Jensen NH, et al. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine?. J Pain Symptom Manage. 1999;18:164–173
  37. Cepeda MS, Farrar JT, Roa JH, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2001;70:351–361
  38. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24:344–354
  39. Fitzgibbon D, Morgan D, Dockter D, Barry C, Kharasch ED. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain. 2003;106:309–315
  40. Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol. 1990;38:121–124
  41. Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007;105:70–78
  42. Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17:185–190
  43. Illum L, Watts P, Fisher AN, et al. Intranasal delivery of morphine. J Pharmacol Exp Ther. 2002;301:391–400
  44. Quigley C, Joel S, Patel N, Baksh A, Slevin M. A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness. J Pain Symptom Manage. 2002;23:7–9
  45. Davis C, Hodder C, Love S, et al. Effect of nebulized morphine and morphine-6-glucuronide on exercise endurance in patients with chronic obstructive airway disease [abstract]. Thorax. 1994;49:393
  46. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003;31:1086–1089
  47. Fisher MB, Vandenbranden M, Findlay K, et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics. 2000;10:727–739
  48. Zheng Z, Fang JL, Lazarus P. Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos. 2002;30:397–403
  49. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos. 2000;28:1352–1360
  50. Yamada H, Ishii K, Ishii Y, et al. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003;28:395–401

PII: S0885-3924(09)00704-0

doi: 10.1016/j.jpainsymman.2009.03.008

Journal of Pain and Symptom Management
Volume 38, Issue 5 , Pages 747-757 , November 2009

Article Tools

* Image Usage & Resolution